Soluble CD30, the Immune Response, and Acute Rejection in Human Kidney Transplantation: A Systematic Review and Meta-Analysis

Mirzakhani, Mohammad; Shahbazi, Mehdi; Akbari, Roghayeh; Dedinská, Ivana; Nemati, Eghlim; Mohammadnia‐Afrouzi, Mousa

doi:10.3389/fimmu.2020.00295

Cited by 16 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NOS quality scores range from 0 to 9. Previous studies (31,32) considered a NOS score ≥6 to indicate high research quality and ≤5 to indicate low research quality, which is consistent with our metaanalysis results. When the quality assessments of the two researchers (Lin and Wen) for an article differed, the disputed issue was resolved through discussion between the two researchers, or, if necessary, the 3rd researcher (Sun) intervened.…”

Section: Data Extraction and Quality Assessmentsupporting

confidence: 91%

The association between different hormone replacement therapy use and the incidence of lung cancer: a systematic review and meta-analysis

Wen¹,

Lin²,

Sun³

2022

J Thorac Dis

View full text Add to dashboard Cite

Background: Many peri-and postmenopausal women use hormone replacement therapy (HRT) to relieve menopausal symptoms. However, the side effects of different HRT use (ever/current/former vs. never HRT use) on lung cancer risk in women were not completely consistent. Thus, we conducted this meta-analysis to examine the connection between current, former or ever HRT use and the incidence of lung cancer among women.Methods: We systematically searched the PubMed, Web of Science, EMBASE, Cochrane Library, SCOPUS, China National Knowledge Infrastructure, Wanfang and VIP databases to identify relevant articles published from the inception of the respective databases to February 18, 2022. On the relationship between different HRT use and the incidence of lung cancer among women. Relevant risk estimates [relative risks (RRs), odds ratio (OR)] were combined based on specific study types. The Newcastle-Ottawa Scale was used to evaluate the quality of included studies. This analysis has been registered in the International prospective register of systematic reviews (PROSPERO; CRD42020219728). Publication bias was tested based on Egger's and Begg's tests.Results: A total of 22 studies (13 prospective cohort studies and 9 case-control studies) were included, comprising 911,194 participants and 17,329 patients. Compared to never HRT users, in pooled cohort studies, current HRT users had a statistically decreased risk of lung cancer [RR 0.91, 95% confidence interval (CI): 0.86-0.97, I 2 =22.9%], and similar results were found among the postmenopausal women with current HRT use (RR 0.91, 95 CI: 0.85-0.98, I 2 =36%), while in pooled case-control studies, ever HRT users had a decreased risk of incidence of lung cancer [odds ratio (OR) 0.75, 95% CI: 0.69-0.81, I 2 =0%] as did female non-smokers with ever HRT use (OR 0.76, 95% CI: 0.66-0.87, I 2 =36.8%).Conclusions: Current or ever HRT use is partly correlated with the decreased incidence of lung cancer in women. Concerns about the incidence of lung cancer can be reduced when perimenopausal and postmenopausal women use current HRT to reduce menopausal symptoms. Meanwhile, given the roles of hormone receptors and relevant genes single nucleotide polymorphism (SNPs) among females, HRT use should be cautiously administered and individualized.

show abstract

Section: Data Extraction and Quality Assessmentsupporting

confidence: 91%

The association between different hormone replacement therapy use and the incidence of lung cancer: a systematic review and meta-analysis

Wen¹,

Lin²,

Sun³

2022

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…A recent metanalysis on 18 studies (1453 total patients) has confirmed a strong association between sCD30 and AR, especially for KTx from deceased donors [ 83 ].…”

Section: Armentioning

confidence: 99%

Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction

Quaglia

Merlotti

Guglielmetti

et al. 2020

IJMS

View full text Add to dashboard Cite

New biomarkers of early and late graft dysfunction are needed in renal transplant to improve management of complications and prolong graft survival. A wide range of potential diagnostic and prognostic biomarkers, measured in different biological fluids (serum, plasma, urine) and in renal tissues, have been proposed for post-transplant delayed graft function (DGF), acute rejection (AR), and chronic allograft dysfunction (CAD). This review investigates old and new potential biomarkers for each of these clinical domains, seeking to underline their limits and strengths. OMICs technology has allowed identifying many candidate biomarkers, providing diagnostic and prognostic information at very early stages of pathological processes, such as AR. Donor-derived cell-free DNA (ddcfDNA) and extracellular vesicles (EVs) are further promising tools. Although most of these biomarkers still need to be validated in multiple independent cohorts and standardized, they are paving the way for substantial advances, such as the possibility of accurately predicting risk of DGF before graft is implanted, of making a “molecular” diagnosis of subclinical rejection even before histological lesions develop, or of dissecting etiology of CAD. Identification of “immunoquiescent” or even tolerant patients to guide minimization of immunosuppressive therapy is another area of active research. The parallel progress in imaging techniques, bioinformatics, and artificial intelligence (AI) is helping to fully exploit the wealth of information provided by biomarkers, leading to improved disease nosology of old entities such as transplant glomerulopathy. Prospective studies are needed to assess whether introduction of these new sets of biomarkers into clinical practice could actually reduce the need for renal biopsy, integrate traditional tools, and ultimately improve graft survival compared to current management.

show abstract

“…8 Although the exact function of CD30 remains unclear, it may participate in signal transduction that leads to NF-κB activation and regulation of the balance between TH1/TH2 responses. 21 CD30 is strongly expressed in several lymphoma subtypes and has been used as a target for the management of Hodgkin lymphomas and anaplastic large cell lymphomas, leading to improvements in the survival curves of the affected patients. 22,23 Although CD30 is expressed in DLBCL, the indeterminate criteria to establish its positivity have led to variable results as demonstrated in our study where we obtained positivity value ranging from 3.5% to 59.1% when a cut-off value of 0% was used, and a range from 2.5% to 36.7% when 20% was used as a reference.…”

Section: Discussionmentioning

confidence: 99%

“…CD30 is a transmembrane glycoprotein expressed on natural killer cells, dendritic cells, regulatory T cells, as well as CD4+ and CD8+ activated T cells 8 . Although the exact function of CD30 remains unclear, it may participate in signal transduction that leads to NF‐κB activation and regulation of the balance between TH1/TH2 responses 21 . CD30 is strongly expressed in several lymphoma subtypes and has been used as a target for the management of Hodgkin lymphomas and anaplastic large cell lymphomas, leading to improvements in the survival curves of the affected patients 22,23 …”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of CD30 expression in diffuse large B‐cell lymphoma: A systematic review with meta‐analysis

Rodrigues-Fernandes

Abreu

Radhakrishnan

et al. 2021

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

Soluble CD30, the Immune Response, and Acute Rejection in Human Kidney Transplantation: A Systematic Review and Meta-Analysis

Cited by 16 publications

References 38 publications

The association between different hormone replacement therapy use and the incidence of lung cancer: a systematic review and meta-analysis

The association between different hormone replacement therapy use and the incidence of lung cancer: a systematic review and meta-analysis

Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction

Prognostic significance of CD30 expression in diffuse large B‐cell lymphoma: A systematic review with meta‐analysis

Contact Info

Product

Resources

About